HighMark Wealth Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.29K Buy
+27
New +$6.24K ﹤0.01% 389
2023
Q1
– Sell
-236
Closed -$36.9K – 605
2022
Q4
$36.9K Buy
236
+1
+0.4% +$144 0.03% 120
2022
Q3
$29K Buy
235
+1
+0.4% +$132 0.02% 130
2022
Q2
$31K Buy
234
+2
+0.9% +$273 0.02% 126
2022
Q1
$32K Buy
232
+1
+0.4% +$139 0.02% 132
2021
Q4
$40K Buy
231
+1
+0.4% +$152 0.03% 131
2021
Q3
$33K Buy
230
+1
+0.4% +$146 0.02% 140
2021
Q2
$30K Buy
229
+1
+0.4% +$131 0.02% 153
2021
Q1
$29K Buy
228
+1
+0.4% +$123 0.02% 141
2020
Q4
$27K Buy
227
+1
+0.4% +$122 0.02% 141
2020
Q3
$26K Buy
226
+1
+0.4% +$118 0.02% 143
2020
Q2
$26K Buy
225
+1
+0.4% +$106 0.03% 115
2020
Q1
$17K Buy
224
+2
+0.9% +$207 0.02% 119
2019
Q4
$23K Hold
222
– – 0.02% 125

Other funds holding DGX

HighMark Wealth Management's DGX Position: Q3 2026 in Review

HighMark Wealth Management opened a new position in Quest Diagnostics (DGX) in Q3 2026: 27 shares worth $6.29K. The stake represents ﹤0.01% of the portfolio and ranks #389 among its holdings. This is a return to the name: HighMark Wealth Management previously reported a position in DGX as recently as Q4 2022.

HighMark Wealth Management first reported a position in DGX in Q4 2019 and has held it in 14 quarters since. The position peaked at $40K in Q4 2021. 1,142 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • HighMark Wealth Management held 27 shares of Quest Diagnostics worth $6.29K as of Q3 2026.
  • Quest Diagnostics was a new HighMark Wealth Management position in Q3 2026.
  • Quest Diagnostics made up ﹤0.01% of HighMark Wealth Management's portfolio in Q3 2026, its #389 holding.
  • HighMark Wealth Management first reported a position in Quest Diagnostics in Q4 2019 and has held it in 14 quarters since.
  • HighMark Wealth Management's Quest Diagnostics position peaked at $40K in Q4 2021.
  • 1,142 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on HighMark Wealth Management's 13F filing for Q3 2026, filed 17 Nov 2026.